Solution Biologics Sdn. Bhd.

solution biologics sdn. bhd. ("solbio") has entered into a market authorisation , manufacturing and commercialisation agreement with cansino biologics inc.based in tianjin, china ("cansinobio", shse:688185, hkex:06185) for the supply of vaccines especially the covid-19 vaccine into malaysia. as part of the manufacturing agreement , solbio is in the process of establishing a fill & finish facility in our current building at technology park malaysia. we are also responsible to market the vaccine, co-developed by cansinobio and the beijing institute of biotechnology, academy of military medical sciences (bib). to the asean countries namely philippines , thailand, singapore, myanmar , vietnam , cambodia , laos and brunei . biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. the annual global biologics market is expected to be approximately usd 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to